Conference Interview #24 of 25
A look back at SABCS 2017: Overtreatment can result in lifelong complications
Sarah Anwar, MDLinx
San Antonio Breast Cancer Symposium 2017
San Antonio, Texas, United States | December 05-09, 2017
At the 2018 Best of SABCS-NY, Sheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast cancer services and professor of surgery at Montefiore Medical Center, Albert Einstein College of Medicine, highlighted some of the works presented in San Antonio.
In this study, from Kuijer, et al, at the Dana Farber Cancer Institute, explores risk overtreatment in patient with breast cancer.
Overtreatment can result in lymphedema, which can be a lifelong condition. According to Dr. Feldman, some patients say that this condition, “is worse than the cancer they had.” In addition, overtreatment can also cause ductal carcinoma in situ, which may result in unnecessary surgery or radiation. Thus, it is important to focus on such conditions when considering treatment.
From this Conference
-
2:34Estrogen receptor expression in luminal tumors & recurrence and metastasisLuminal breast cancer subtypes are characterized by estrogen-receptor and estrogen-related genes, which sets them apart from other tumors that are not hormonally driven.
Angela DeMichele, MD, MSCE -
1:50Conversion to response after failed immunotherapyIn some patients with cancer who have failed immune checkpoint blockade treatment, the addition of radiotherapy may bring about conversion to response.
Silvia Formenti, MD -
1:50Tumor types, immune response, and radiotherapyOne of the most exciting areas of study currently being conducted in breast cancer is the potential of radiation therapy to convert tumors into an in situ vaccine. Silvia...
Silvia Formenti, MD -
1:29The future of breast cancer treatmentThe future of breast cancer treatment should center on risk-stratifying patients in a better way, according to Tatiana Prowell, MD, breast cancer scientific liaison, FDA...
Tatiana Prowell, MD -
7:15Seamless designs for clinical trials: A new wave in drug development, explainedWith the movement toward developing more targeted therapies, the FDA has updated its drug development system to include what they have designated as ‘seamless...
Tatiana Prowell, MD -
1:32The benefits and hurdles of early, concurrent, palliative careThe difference between hospice care and palliative care is an important distinction to make, and the shortage in palliative care providers must be addressed if clinicians are...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM
This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.
